COMPARISON OF QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BONE DISEASE (MBD)  BEFORE AND AFTER BISPHOSPHONATE THERAPY BASED ON CALCIUM LEVELS

Fachrizal Arfani Prawiragara; Hilmia Fahma; Debrina Kusuma Devi; Leonardo Tedjaprasadja

doi:10.14710/dmj.v15i4.54076

DOI: https://doi.org/10.14710/dmj.v15i4.54076

COMPARISON OF QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BONE DISEASE (MBD) BEFORE AND AFTER BISPHOSPHONATE THERAPY BASED ON CALCIUM LEVELS

*Fachrizal Arfani Prawiragara - Department of Orthopaedic and Traumatology, Faculty of Medicine, Universitas Pembangunan Nasional "Veteran" Jawa Timur, Surabaya, Indonesia, 60294, Indonesia

Hilmia Fahma - Department of Psychiatric, Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jawa Timur, Indonesia, Indonesia

Debrina Kusuma Devi - Department of Internal Medicine, Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jawa Timur, Indonesia, Indonesia

Leonardo Tedjaprasadja - Department of Public Health, Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jawa Timur, Indonesia, Indonesia

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

BibTex Citation Data :

@article{dmj54076,
    author = {Fachrizal Prawiragara and Hilmia Fahma and Debrina Kusuma Devi and Leonardo Tedjaprasadja},
    title = {COMPARISON OF QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BONE DISEASE (MBD)  BEFORE AND AFTER BISPHOSPHONATE THERAPY BASED ON CALCIUM LEVELS},
    journal = {Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal)},
  volume = {15},
    number = {4},
    year = {2026},
    keywords = {Bisphosphonates therapy; Karnofsky score; Metastatic bone disease; QoL; Serum calcium level},
    abstract = {  Background:  Metastatic bone disease (MBD) is a frequent complication in advanced cancer, often resulting in pain, limited mobility, and reduced QoL. Bisphosphonates are effective in minimizing skeletal-related events by suppressing osteoclast activity.  Objective:  To assess the impact of bisphosphonate therapy on serum calcium levels and QoL in patients with metastatic bone disease.  Methods:  A retrospective cohort study was conducted involving 228 MBD patients treated at Dr. Soetomo General Hospital from 2015 to 2020. Surgical eligibility was determined using the Abdurrahman Score. Pre- and post-treatment data on serum calcium levels and Karnofsky Scores were collected and analyzed using paired t-tests.  Results:  In the surgical group, the mean Karnofsky Score improved from 46.67 ± 12.69 to 77.67 ± 9.35 (p < 0.001), while serum calcium levels decreased from 10.1 ± 1.20 to 7.3 ± 1.01 (p < 0.001). In the non-surgical group, Karnofsky Scores increased from 36.67 ± 12.22 to 49.35 ± 13.15, and calcium levels declined from 10.2 ± 1.18 to 7.6 ± 1.33 (both p < 0.001).  Conclusion:  Bisphosphonate therapy significantly enhances QoL and reduces serum calcium levels in patients with metastatic bone disease. The combination of surgical management and bisphosphonate therapy yields superior functional outcomes compared to non-surgical treatment. },
   issn = {2540-8844},   pages = {316--321}  doi = {10.14710/dmj.v15i4.54076},
    url = {https://ejournal3.undip.ac.id/index.php/medico/article/view/54076}
}

Citation Format:

Abstract

Background: Metastatic bone disease (MBD) is a frequent complication in advanced cancer, often resulting in pain, limited mobility, and reduced QoL. Bisphosphonates are effective in minimizing skeletal-related events by suppressing osteoclast activity. Objective: To assess the impact of bisphosphonate therapy on serum calcium levels and QoL in patients with metastatic bone disease. Methods: A retrospective cohort study was conducted involving 228 MBD patients treated at Dr. Soetomo General Hospital from 2015 to 2020. Surgical eligibility was determined using the Abdurrahman Score. Pre- and post-treatment data on serum calcium levels and Karnofsky Scores were collected and analyzed using paired t-tests. Results: In the surgical group, the mean Karnofsky Score improved from 46.67 ± 12.69 to 77.67 ± 9.35 (p < 0.001), while serum calcium levels decreased from 10.1 ± 1.20 to 7.3 ± 1.01 (p < 0.001). In the non-surgical group, Karnofsky Scores increased from 36.67 ± 12.22 to 49.35 ± 13.15, and calcium levels declined from 10.2 ± 1.18 to 7.6 ± 1.33 (both p < 0.001). Conclusion: Bisphosphonate therapy significantly enhances QoL and reduces serum calcium levels in patients with metastatic bone disease. The combination of surgical management and bisphosphonate therapy yields superior functional outcomes compared to non-surgical treatment.

Fulltext View|Download Email colleagues

Keywords: Bisphosphonates therapy; Karnofsky score; Metastatic bone disease; QoL; Serum calcium level

Article Metrics:

Article Info

Section: Original Articles

Language : EN

In Vol 15, No 4 (2026): JURNAL KEDOKTERAN DIPONEGORO (DIPONEGORO MEDICAL JOURNAL)

D’Oronzo S, Coleman R, Brown J, Silvestris F. Metastatic bone disease: Pathogenesis and theraupetic options up-date on bone metastasis management. Journal of Bone Oncology. 2019 Aug; 15: 1-12
Sousa S, Clézardin P. Bone-Targeted therapies in cancer-induced bone disease. Calcif Tissue Int. 2018 Feb;102(2):227–50
Macedo F, Ladeira K, Pinho F, Saraiva N, Bonitto N, Pinto L, Goncalves F. Bone metastases: An overview. Oncology Reviews. 2017 May; 11(1): 43-49
Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, et al. Bone metastases. Nat Rev Dis Prim. 2020 Oct;6(1):83
Zhang H, Zhu W, Biskup E, Yang W, Yang Z, Wang H, et al. Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data. J bone Oncol. 2018 Jun;11:38–50
Anastasopoulou C, Mewawalla P. Malignancy-Related Hypercalcemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482423/
Wang M, Xia F, Wei Y, Wei X. Molecular mechanisms and clinical management of cancer bone metastasis. Bone Res [Internet]. 2020;8(1):30. Available from: https://doi.org/10.1038/s41413-020-00105-1
Tauro M, Lynch CC. Cutting to the Chase: How Matrix Metalloproteinase-2 Activity Controls Breast-Cancer-to-Bone Metastasis. Cancers (Basel). 2018 Jun;10(6)
Wawrzyniak A, Balawender K. Structural and metabolic changes in bone. Animals. 2022 July; 12: 1-22
Arjunan D, Bhadada T, Mohankumar SB, Bhadada SK. Non-biological Antiresorptive: Bisphosphonates. Indian J Orthop. 2023 Dec;57(Suppl 1):120–6
Mbese Z, Aderibigbe BA. Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer. Int J Mol Sci. 2021 Jun;22(13)
Joenputri N. Terapi Bifosfonat untuk Pasien Osteoporosis Pasca Menopause. Cermin Dunia Kedokt. 2020;47(10):692
Sutantio AA, Soetojo, BW, Dwipayana R. Epidural spinal cord compression metastasis from nasopharyngeal carcinoma: report a rare case. International Surgery Journal. 2023; 10(3): 467-470
Mahyudin F. Diagnosis dan Terapi TUMOR MUSKULOSKELETAL (multidiciplinary approach). Vol. 53, FKUI Press. Jakarta; 2017. 1689–1699 p
Hansen BH, Keller J, Laitinen M, Berg P, Skjeldal S, Trovik C, et al. The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities. Acta Orthop Scand Suppl. 2004 Apr;75(311):11–5
Tharmalingam S, Chow E, Harris K, Hird A, Sinclair E. Quality of life measurement in bone metastases: A literature review. J Pain Res. 2008 Oct;1:49–58
. Damron TA, Mann KA. Fracture risk assessment and clinical decision making for patients with metastatic bone disease. J Orthop Res. 2020 June; 38(6): 1175-1190
Allen, MR. Recent advances in understanding biphosphonate effects on bone mechanical properties. Curr Osteoporos Rep. 2018 April; 16(2): 198-204
Farrell KB, Karpeisky A, Thamn DH, Zinnen S. Biphosphonate conjugation for bone specific drug targeting. Bone Reports. 2018; 9: 47-60
Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: differential diagnosis and treatment. CA Cancer J Clin. 2018 Sept; 68(2): 377-386
Wang Y, Qiming X, Li Y, Su Y, Wang L, Wang X, Ge J, Jing H, Guo Y, Chen Y, Li X, Zhuang J-L, Tan J, Wang X, Zhong L, Luo J, Zhao P, Fan S, Ren J, Yang H, Bao L. Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease. Cancer Pathogenesis and Therapy. 2025 Jul; 3(4): 280-292

Last update:

No citation recorded.

Last update:

No citation recorded.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Authors who publish with this journal agree to the following terms: - Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC-BY-NC-SA) that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal. - Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal. - Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).